Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial
Circulation: Cardiovascular Interventions · 2024
DOI: 10.1161/circinterventions.123.013192 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Ziad A Ali und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Foundation, New York, NY (Z.A.A., J.J.G., J.H., A.G., O.B.-Y., B.R.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The importance of complete revascularization after percutaneous coronary intervention (PCI) in patients with left main coronary artery disease is uncertain. We investigated the clinical impact of complete revascularization in patients with left main coronary artery disease undergoing PCI in the EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization). METHODS: Composite rates of death or myocardial infarction (MI) following PCI during 5-year follow-up were examined in 903 patients based on core laboratory definitions of anatomic and functional complete revascularization, residual SYNTAX score (The Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery), and residual Jeopardy Score (rJS). RESULTS: The risk of death or MI did not vary based on anatomic, functional, or residual SYNTAX score complete revascularization but did differ according to the rJS (5-year rates 17.6%, 19.5%, and 38.9% with rJS 0, 2, and ≥4, respectively; P =0.006). The higher rate of death or MI with rJS≥4 versus rJS≤2 was driven conjointly by increased mortality (adjusted hazard ratio, 2.29 [95% CI, 1.11–4.71]; P =0.02) and spontaneous MI (adjusted hazard ratio, 2.89 [95% CI, 1.17–7.17]; P =0.02). The most common location for untreated severe stenoses in the rJS≥4 group was the left circumflex artery (LCX), and the post-PCI absence, compared with the presence, of any untreated lesion with diameter stenosis ≥70% in the LCX was associated with reduced 5-year rates of death or MI (18.9% versus 35.2%; hazard ratio, 0.48 [95% CI, 0.32–0.74]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiovascular Research Foundation, New York, NY (Z.A.A., J.J.G., J.H., A.G., O.B.-Y., B.R.).
- St Francis Hospital and Heart Center, Roslyn, NY (Z.A.A., K.K.G., D.S.).
- Weill-Cornell Medical Center/New York-Presbyterian Hospital, NY (S.C.).
- Erasmus Medical Center, Rotterdam, the Netherlands (A.P.K.).
- University Hospitals Cleveland Medical Center, OH (J.F.S.).
- University of Galway, Ireland (P.W.S.).
ORCID-Profile: Ziad A Ali, Anthony Gallo, Doosup Shin, Shmuel Chen, Björn Redfors, Arie Pieter Kappetein, Patrick W Serruys
Zitieren
APA
Ali, Z. A., Garcia, J. J., Karimi Galougahi, K., Horst, J., Gallo, A., Shin, D., Ben-Yehuda, O., Chen, S., Redfors, B., Kappetein, A. P., Sabik, J. F., Serruys, P. W., & Stone, G. W. (2024). Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.123.013192
Vancouver
Ali ZA, Garcia JJ, Karimi Galougahi K, Horst J, Gallo A, Shin D, et al. Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.123.013192
BibTeX
@article{Ali2024,
author = {Ali, Ziad A and Garcia, Javier Jas and Karimi Galougahi, Keyvan and Horst, Jennifer and Gallo, Anthony and Shin, Doosup and Ben-Yehuda, Ori and Chen, Shmuel and Redfors, Björn and Kappetein, Arie Pieter and Sabik, Joseph F and Serruys, Patrick W and Stone, Gregg W},
title = {Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
doi = {10.1161/circinterventions.123.013192}
}
EUVIMED